Overview

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Status:
NOT_YET_RECRUITING

Trial end date:
2029-05-30

Target enrollment:

Participant gender:

Summary

To explore the efficiency and safety of Tislelizumab combinated with carboplatin and polymeric micellar paclitaxel as a new neoadjuvant treatment regimen for resectable HNSCC patients with clinical positive lymph node metastasis

Phase:

PHASE2

Details

Lead Sponsor:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Treatments:

Carboplatin
tislelizumab